Novo submits application to FDA for long-lasting haemophilia medication
As anticipated Novo Nordisk has submitted an application to the US authorities to register a new, long-lasting medication for haemophilia.
BY STEFAN SINGH KAILAY
After a long waiting period, Novo Nordisk has submitted an application to US authorities for the registration of its latest, long-lasting medication for haemophilia, nonacog beta pegol, also known as N9-GP. The company states this Monday afternoon.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
